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a b s t r a c t
Pd-catalysed reactions of 2-Cl, 2-Br and 2-I derivatives of a 6-chloropurine nucleoside with benzamide
have been compared, using Pd2dba3, Xantphos and Cs2CO3 in toluene, between 20 and 80 !C. The reactiv-
ity order was 2-I > 2-Br > 6-Cl! 2-Cl. The 2-I substituent could be replaced even at 0 !C, under conditions
disclosed here for the first time. On the other hand, the replacement of the chlorine atom at position 2 (2-
Cl) required 110 !C.
" 2012 Elsevier Ltd. All rights reserved.
In spite of the remarkable advances in transition metal-catalysed
cross-coupling reactions for the formation of carbon–carbon and car-
bon–heteroatombonds inheterocycles andnucleosides,1 there contin-
ues to be an increasing demand of new improvements. Control of the
cross couplings of dihalo or trihalo derivatives of purines and their
nucleosides with nucleophiles has interest because of the biological
ormedicinal significance of the resulting products. In particular, selec-
tive substitutions can provide alternative routes to the analogues and
surrogates of purine-derived known anticancer agents2 and, in
general, to adenosine receptor agonists or antagonists.3
In the past years we have been interested in ring modifications
of nucleosides, aimed at preparing endo and exo 15N-labeled sam-
ples. Ring nitrogen labels were introduced by means of new ring-
opening–ring-closing reactions, while exocyclic labels came from
Buchwald–Hartwig amidation reactions of chloropurine nucleo-
sides with [15N]benzamide.4 In this way, we achieved the synthesis
of [15N2]adenosines and [15N2]-20-deoxyadenosines4d and of
[15N2]guanosines.4e
In this context, we planned to compare the reactivity of dihalo
derivatives of 9-(20,30,50-tri-O-acetylribofuranosyl)purines 1–3 among
them and against different kinds of amides. Differences were
expected,1 but we found out suitable conditions for the selective
replacement of one halogen or the other, including those for the
replacement of I at 0 !C, which we report here for the first time.
Purine nucleosides, owing to their sensitivity to Lewis and Brön-
sted acids, which may give rise to the cleavage of the anomeric
bonds and removal of the protecting groups (PGs), and to bases—
with the removal of some PGs as well—are ideal substrates for test-
ing the performance of a catalytic system; mild reaction conditions
and short reaction times are a must, otherwise decomposition
products predominate. In sharp contrast to what happens in many
cross-coupling reactions, the substrates are often4e much more
expensive than the Pd and P reagents. In the present work we have
used nucleosides with Ac groups as PGs, as they were the most
convenient during the synthesis of the starting materials. As it is
also known, unlike SNAr-like reactions, where the order of substi-
tution of aryl halides by a nucleophilic nitrogen is usually
F > Cl > Br > I,5 in Pd-catalysed reactions the opposite order is
observed, I > Br! Cl >>> F,1 since the insertion of Pd0 into the
C–X bond is generally the rate-determining step. Moreover, in
2,6-dichloro derivative 1, position 6 is the most reactive (both in
Pd-catalysed and SNAr/SNHet processes).4e,5 In the case of 6-
chloro-2-iodo-9-isopropylpurine, Piguel and Legraverend showed
that the Pd-catalysed reaction takes place at the C2 position with
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full regioselectivity,6 that is, the preference of Pd0 to insert into the
C2–I bond overcomes the higher intrinsic reactivity of position 6 in
SNHet reactions. In this connection, 2-bromo-6-chloro derivative 2
is a more challenging case, that is, a very appropriate substrate for
the evaluation of the relative significance of both effects.
Thus, we treated 1–37 with benzamide as a representative nitro-
gen source, in the presence of 1 mol % of Pd2dba3"CHCl3 (dba =
dibenzylideneacetone = 1,5-diphenyl-1,4-pentadien-3-one) and
3 mol % of Xantphos [4,5-bis(diphenylphosphino)-9,9-dimethylx-
anthene],8 at different temperatures, as shown in Table 1. Although
we had the feeling that the amount of catalyst could be even lower,
we were more interested in avoiding long reaction times (owing to
the possible decomposition of the nucleosidic substrates, as
mentioned).
With 2,6-dichloro derivative 1, a temperature of 80 !C was
required for its total conversion to 4 (Table 1, compare entries
1–3).9 Substitution only took place on C6 (the product of substitu-
tion at C2, see 5, was not detected, under these conditions).
With 2 and 3, the replacements of Br and I at C2, respectively,
were complete at 50 !C (Table 1, entries 5 and 8) to give 5.10 The
mass spectra of the products, showing in one case the replacement
of 2-Br (but not that of 6-Cl) and in the other one the replacement
of 2-I (but not that of 6-Cl), were conclusive. The reactivity differ-
ences between 2 and 3 were, however, significant at 20 !C (com-
pare entries 4 to 7). To summarize, the reactivity order appeared
to be 2-I > 2-Br > 6-Cl! 2-Cl. The order 2-I > 2-Br > 2-Cl was
expected, but the ‘position’ of 6-Cl in this scale was unknown.
The case of 2 (2-Br vs 6-Cl) was the more interesting one. Below
80 !C we only observed the replacement of 2-Br (5, entry 5). At
80 !C, we detected a minor disubstitution product (footnote to
entry 6 of Table 1, see 6 below). Regarding the amount of base,
the same outcome was obtained with 60 mol % as with 110 mol %
of Cs2CO3; therefore, in these heterocyclic systems an excess of
base is not crucial (saving of base is possible). Moreover, without
Pd/Xantphos but with an excess of Cs2CO3, the reactions were very
slow since, after 24 h at 80 !C in toluene, <10% of substitution at C6
took place. Even at 100 !C for 24 h with 2 equiv PhCONH2 and
200 mol % of Cs2CO3, in the presence of Xantphos (but without
Pd, of course), the substitution percentages were low (around
10%). Thus, the disubstitution byproduct—the observation of sub-
stitution at C6 in the experiments at 80 !C for 61 h, indicated in
entries 6 and 9 of Table 1—does not come from a SNAr-like
mechanism.
We then repeated the reaction of 2 with twice the amount of
PhCONH2, at 85 !C, with only 1 mol % of Pd2dba3"CHCl3, 3 mol %
of Xantphos and 110 mol % of Cs2CO3, as indicated in Scheme 1.
Compound 2 was fully converted into 2,6-dibenzamido derivative
6.11 The isolated yield was 85%.
Therefore, it appears that the Pd0 insertion occurs selectively at
the more reactive C2–Br bond, but once this bromine atom has
been replaced to a large extent, the insertion of Pd0 into the
C6–Cl bond becomes competitive when the reaction temperature
is P80 !C.
As the reaction of 3 had been complete at rt (Table 1, entry 7),
we examined such a reaction at 0 !C. In toluene, the formation of
the active Pd–Xantphos species13 (that is, the dba-to-Xantphos
exchange) was not observed and benzamide was quite insoluble,
so that the reaction did not go forward. However, it was sufficient
to warm Pd2dba3 and Xantphos in toluene (at 60 !C for a few sec-
onds) and, after cooling to 0 !C, to add a solution of 3 and benzam-
ide in a similar volume of 1,4-dioxane to note a smooth progress of
the cross-coupling reaction, as shown in entry 1 of Table 2, with no
secondary reactions (no deacetylation byproducts were observed
at all). To the best of our knowledge (exhaustive SciFinder search),
there are no precedents of efficient Pd-catalysed amidations
carried out below room temperature.14 The replacement of the io-
dine atom of 3 was selective under these conditions as the bromo
derivative, 2, did not react at all.
Could other similarly activated iodine atoms be selectively re-
placed below rt? We examined the Pd-catalysed reaction of
PhCONH2 with two additional substrates (7 and 8, Table 2).15 Good
Table 1
Pd0-catalysed reactions of 2,6-dihalopurine nucleosides with benzamide, at different temperaturesa
Entry Compound T (!C) Time Conv. (%) Product, yieldb (%)
1 1 20 48 h 0 —
2 1 50 6 h 15 4, 10
3 1 80 6 h 100 4, 87
4 2 20 48 h 40 5, 35
5 2 50 3 h 100 5, 86
6 2 80 1 h 100 5, 80c
7 3 20 24 h 100 5, 88
8 3 50 2 h 100 5, 87
9 3 80 40 min 100 5, 82c
a Reaction conditions: 0.1 M in anhyd. toluene, under Ar, 1.0 mol % of Pd2dba3"CHCl3 (that is, 0.02 equiv of Pd0), 3.0 mol % of Xant-
phos. Some experiments repeated with Pd2dba3 and Pd(dba)2 (2 mol % in this last case) did not show significant differences.12
b Isolated yields after flash column chromatography.
c The dibenzamido derivative was detected (5–10%). See the main text.
Scheme 1. Pd0-catalysed double substitution of 2 with benzamide.
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conversions were observed, although the reactions were slightly
slower than in the case of 3. To shorten the reaction times, we
enhanced the substrate concentration to 0.2 M (see entries 2, 3
and 5) and/or that of the catalyst (entries 4 and 5); of course, there
is room for improvement by operating at higher concentrations
and with a large excess of PhCONH2, but we did not examine it.
On the other hand, as it could be expected, iodobenzene did not re-
act at all under these so mild conditions. In other words, only the
most reactive C–I bonds undergo the insertion of the Pd0/Xantphos
complex below rt.
Finally, to evaluate the scope of the reaction, other N-nucleophiles
were subjected to the standard conditions (Table3).Wechose1 and2
(instead of 3) as substrates because they are more challenging in-
stances, never reported before, where the substitutions at C2 and
C6 can compete. Isobutyramide, O-benzyl carbamate,16 and N-2-
nitrobenzenesulfonylglycine methyl ester (o-nosyl-NHCH2COOMe,
Ns-Gly-OMe) were chosen as nucleophile models. Although there
are precedents of Pd-catalysed N-arylations of sulfonamides,17 we
have not found examples with the less reactive o-nosylamides;18
the Ns protecting group is more readily removed than standard
sulfonyl groups.19 Reactions ran parallel to those of benzamide and
isobutyramide, although they were slower.20
Replacement of halo substituents by two different amides, car-
bamates or sulfonamides seemed possible and could be an entry to
diverse conjugates of 2,6-diamino-purines. As an example or ‘proof
of concept’ we treated 5 with benzyl carbamate and Cs2CO3 in the
presence of Pd0/Xantphos (Scheme 2), in toluene at 85 !C for 5 h,
which gave disubstituted product 17. The conversion was com-
plete but a partial decomposition of the carbamate group was
noted (the isolated yield was around 60%).21
Table 2
Pd0-catalysed reactions of iodo derivatives 3, 7 and 8 with benzamide at 0 !Ca
Entry Iodo deriv., concn. Pd2dba3, mol % Time Conv. (%) Product, yield (%)
1 3, 0.1 M 1 48 h 100 5, 93
2 3, 0.2 M 1 24 h 100 5, 96
3 7, 0.2 M 1 36 h 100 9, 95
4 8, 0.1 M 2.5 48 hb 100 10, 94b
5 8, 0.2 M 2.5 28 h 100 10, 95
a Pd2dba3"CHCl3 (0.040 mmol) and Xantphos (0.120 mmol) in anhyd. toluene (10 mL) were warmed under Ar. As soon as the wine-red
suspension became greenish yellow (formation of the Pd–Xantphos complex),13 the flask was cooled to 0 !C (stock solution stored under Ar).
For entries 2, 3 and 5, an aliquot (2.5 mL) was added via syringe to a vial (bath at 0 !C) with anhyd. Cs2CO3 (1.1 mmol). Afterwards, the iodo
derivative (1.0 mmol) and benzamide (1.2 mmol) in 1,4-dioxane (2.5 mL), where benzamide is soluble, was added via syringe, and stirring
was maintained at 0 !C for the time indicated, always under Ar.
b This experiment was repeated using a 1:2.1 Pd/P ratio instead of the standard 1:3 ratio, with a practically identical efficiency (conversion/
time).
Table 3
Pd0-catalysed reactions of 1 and 2 with amides, carbamates or nosylamides at 80 !C
for 6 h, with the reagent ratios of Table 1
Entry Compd. Nucleoph. Product Yield %
1 1
11
85
2 1
12
77
3 1
N
NN
N
Rf
N
Cl
Ns
O
Me
13
87
4 2
14
82
5 2
15
78
6 2
16
84
Scheme 2. Preparation of a N2,N6-disubstituted 2,6-diaminopurine.
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Only the activation of the 2-Cl substituent of 1 (and of 11–13)
remained a challenge. We had attempted this replacement by forc-
ing the reaction conditions in refluxing 1,4-dioxane but the crude
contained many decomposition products. However, the conversion
of 1 into the dibenzamido derivative, 6, could be achieved in tolu-
ene at 108–110 !C (bath temperature), in 90% isolated yield, within
6 h, with 2.5 mol % of Pd2(dba)3, 7.5 mol % of Xantphos and
110 mol % of Cs2CO3.
In summary, Pd0 and Xantphos are very suitable partners for the
coupling of halopurine nucleosides with amides (either carboxam-
ides, carbamates or nosylamides). The regioselectivity–reactivity
order is 2-I > 2-Br > 6-Cl! 2-Cl (the 2-I > 2-Br > 2-Cl order was ex-
pected, but the point was to establish the ‘position’ of 6-Cl). We
have achieved the replacement of the iodine atom of 6-iodo-2-
chloro derivative 3 (and other similar iodo derivatives) at 0 !C, a
temperature at which the bromine of 2 is not substituted at all.
Such a reactivity order permits to manipulate 2,6-dihalopurines
in a proper way to attach protected amine groups either at C2 or
C6. Via Pd-catalysed processes, it is also feasible to prepare differ-
ently N2,N6-disubstituted diaminopurines (potential nucleoside
conjugates). Finally, even the more reluctant 2-Cl substituent can
be replaced by a benzamido group, in toluene at 110 !C, with a
minimum amount of Cs2CO3 and reaction times as short as possi-
ble to avoid byproducts coming from the decomposition or sapon-
ification of sensitive substrates (protected purine nucleosides).
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